Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms

Vascular Diseases Research Unit, The Institute of Cardiovascular Research, Ninewells Hospital and Medical School, Dundee, Scotland DD1 9SY, UK.
Free Radical Biology and Medicine (Impact Factor: 5.74). 10/2005; 39(5):584-9. DOI: 10.1016/j.freeradbiomed.2005.04.020
Source: PubMed


The aetiology of chronic fatigue syndrome (CFS) is unknown; however, recent evidence suggests excessive free radical (FR) generation may be involved. This study investigated for the first time levels of 8-iso-prostaglandin-F(2 alpha)-isoprostanes alongside other plasma markers of oxidative stress in CFS patients and control subjects. Forty-seven patients (18 males, 29 females, mean age 48 [19--63] years) who fulfilled the Centres for Disease Control classification for CFS and 34 healthy volunteers (13 males, 21 females, 46 [19--63] years) were enrolled in the study. The CFS patients were divided into two groups; one group had previously defined cardiovascular (CV) risk factors of obesity and hypertension (group 1) and the second were normotensive and nonobese (group 2). Patients had significantly increased levels of isoprostanes (group 1, P=0.007; group 2, P=0.03, unpaired t test compared to controls) and oxidised low-density lipoproteins (group 2, P=0.02) indicative of a FR attack on lipids. CFS patients also had significantly lower high-density lipoproteins (group 1, P=0.011; group 2, P=0.005). CFS symptoms correlated with isoprostane levels, but only in group 2 low CV risk CFS patients (isoprostanes correlated with; total symptom score P=0.005; joint pain P=0.002; postexertional malaise P=0.027, Pearson). This is the first time that raised levels of the gold standard measure of in vivo oxidative stress (isoprostanes) and their association with CFS symptoms have been reported.

Download full-text


Available from: Vance Spence,
  • Source
    • "As the prime source of reactive oxygen species (ROS) within the body, there may be a link between mitochondrial dysfunction and ME/CFS through oxidative stress (Morris and Maes 2014a; Meeus et al. 2013). Oxidative stress has been linked to ME/CFS through the detection of reduced antioxidant levels and increases in signals of oxidative damage including glutathione, peroxidated lipids and damaged tissue (Maes et al. 2011; Kennedy et al. 2005). Typically ROS production may be triggered by cytokines to attack pathogen but can create oxidative stress if production is too high, therefore linking a chronic inflammatory response to oxidative stress as proposed for ME/CFS (Morris and Maes 2014a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating long-term multisystem disorder with a central and inexplicably persistent fatigue symptom that is unable to be relieved by rest. Energy metabolism and oxidative stress have been recent focal points of ME/CFS research and in this study we were able to elucidate metabolic pathways that were indicative of their dysfunction. Blood and urine samples were collected from 34 females with ME/CFS (34.9 ± 1.8 SE years old) and 25 non-ME/CFS female participants (33.0 ± 1.6 SE years old). All samples underwent metabolic profiling via 1D 1H Nuclear magnetic resonance spectroscopy and quantitated metabolites were assessed for significance. Blood glucose was elevated while blood lactate, urine pyruvate, and urine alanine were reduced indicating an inhibition of glycolysis that may potentially reduce the provision of adequate acetyl-CoA for the citric acid cycle. We propose that amino acids are being increasingly used to provide an adequate carbohydrate source for the citric acid cycle. We suggest that this is via glutamate forming 2-oxoglutarate through an enzyme that deaminates it and subsequently elevates blood aspartate. Dysfunctional energy metabolism appears to have impacted creatinine and its elevation in urine suggests that it may be used as an alternative for anaerobic ATP production within muscle. A decrease in blood hypoxanthine and an increase in urine allantoin further suggest the elevation of reactive oxygen species in ME/CFS patients. These findings bring new information to the research of energy metabolism, chronic immune activation and oxidative stress issues within ME/CFS.
    Metabolomics 05/2015; 11(6). DOI:10.1007/s11306-015-0816-5 · 3.86 Impact Factor
  • Source
    • "ng HMGB1 , and indirectly stimu - late the production of secondary DAMP signaling ( Lotze et al . , 2007 ) . Interestingly , approximately 40% of all FDA - approved anticancer drugs have been shown to induce ROS ( Chen et al . , 2007 ) . Oxidative stress can produce behavioral toxicities , such as chronic fatigue syndrome ( Logan and Wong , 2001 ; Kennedy et al . , 2005 ) , mild cognitive impairment ( Fukui et al . , 2002 ; Pratico et al . , 2002 ) , and diabetic neuropathy ( Nagamatsu et al . , 1995 ; Low et al . , 1997 ; Vincent et al . , 2004 ) . Furthermore , there is evidence to suggest that chemotherapy - induced neuropathy ( Areti et al . , 2014 ) and cognitive impairment ( Aluise et al . , 2010"
    [Show abstract] [Hide abstract]
    ABSTRACT: While chemotherapeutic agents have yielded relative success in the treatment of cancer, patients are often plagued with unwanted and even debilitating side-effects from the treatment which can lead to dose reduction or even cessation of treatment. Common side effects (symptoms) of chemotherapy include (i) cognitive deficiencies such as problems with attention, memory and executive functioning; (ii) fatigue and motivational deficit; and (iii) neuropathy. These symptoms often develop during treatment but can remain even after cessation of chemotherapy, severely impacting long-term quality of life. Little is known about the underlying mechanisms responsible for the development of these behavioral toxicities, however, neuroinflammation is widely considered to be one of the major mechanisms responsible for chemotherapy-induced symptoms. Here, we critically assess what is known in regards to the role of neuroinflammation in chemotherapy-induced symptoms. We also argue that, based on the available evidence, neuroinflammation is unlikely the only mechanism involved in the pathogenesis of chemotherapy-induced behavioral toxicities. We evaluate two other putative candidate mechanisms. To this end we discuss the mediating role of damage-associated molecular patterns (DAMPs) activated in response to chemotherapy-induced cellular damage. We also review the literature with respect to possible alternative mechanisms such as a chemotherapy-induced change in the bioenergetic status of the tissue involving changes in mitochondrial function in relation to chemotherapy-induced behavioral toxicities. Understanding the mechanisms that underlie the emergence of fatigue, neuropathy, and cognitive difficulties is vital to better treatment and long-term survival of cancer patients.
    Frontiers in Neuroscience 05/2015; 9. DOI:10.3389/fnins.2015.00131 · 3.66 Impact Factor
  • Source
    • "Vecchiet et al. (2003) found that patients with CFS showed worse oxidative stress in vivo, including enhanced LDL oxidative susceptibility and thiobarbituric acid reactive substances (TBARS). The level of fatigue in CFS correlates with the blood concentration of 8-isoprostane, a lipid peroxidation marker, indicating that oxidative stress is an important factor associated with fatigue (Kennedy et al., 2005). Eldadah (2010) reported that a number of people felt that they tire easily with increasing age. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sesamin has anti-oxidative functions in vivo. Fatigue is caused in part by oxidative stress. We evaluated whether sesame lignans (sesamin/episesamin = 1/1, 10 mg) with vitamin E (55 mg of alpha-tocopherol) (SVE) could improve subjective statuses and anti-oxidative capacity in humans using questionnaires on fatigue, sleep and physical appearance, as well as low-density lipoprotein oxidation lag time. A placebo-controlled, double-blind, parallel-group study was conducted with subjects experiencing daily fatigue. After a run-in period, subjects were administered oral SVE or a placebo (P) for 8 weeks. A questionnaire regarding fatigue, sleep and physical appearance was conducted at 0, 4, and 8 weeks. Plasma low-density lipoprotein oxidation lag time was measured as an indicator of anti-oxidative capacity. The per-protocol analysis revealed significant improvements in fatigue status at 4 and 8 weeks compared to 0 weeks in both groups (p < 0.01), and sleep and physical appearance at 8 weeks compared to 0 weeks only in the SVE group (p < 0.01). There were no significant differences observed between the groups. According to the 72-subject subgroup analysis (aged 40 and over), the sleep and physical appearance significantly improved compared to the P group (p < 0.05), and fatigue status showed a tendency for improvement compared to the P group. Anti-oxidative capacity in the SVE group significantly increased compared to the P group (p < 0.01). No adverse events relating to SVE supplementation were confirmed. These results suggest SVE supplementation could safely alleviate daily fatigue and oxidative stress.
    Global journal of health science 03/2015; 7(6). DOI:10.5539/gjhs.v7n6p1
Show more